BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22305511)

  • 1. Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?
    Iehara T; Hiyama E; Tajiri T; Yoneda A; Hamazaki M; Fukuzawa M; Hosoi H; Sugimoto T; Sawada T
    Eur J Cancer; 2012 Jul; 48(11):1707-12. PubMed ID: 22305511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of bone marrow evaluation in the staging of patients with otherwise localized, low-risk neuroblastoma.
    Russell HV; Golding LA; Suell MN; Nuchtern JG; Strother DR
    Pediatr Blood Cancer; 2005 Dec; 45(7):916-9. PubMed ID: 16078212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies.
    van Noesel MM; Hählen K; Hakvoort-Cammel FG; Egeler RM
    Cancer; 1997 Sep; 80(5):834-43. PubMed ID: 9307181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
    London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
    J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.
    Minard V; Hartmann O; Peyroulet MC; Michon J; Coze C; Defachelle AS; Lejars O; Perel Y; Bergeron C; Boutard P; Leverger G; Stephan JL; Thyss A; Chastagner P; Couillault G; Devalck C; Lutz P; Mechinaud F; Millot F; Plantaz D; Rialland X; Rubie H
    Br J Cancer; 2000 Oct; 83(8):973-9. PubMed ID: 10993641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.
    Taggart DR; London WB; Schmidt ML; DuBois SG; Monclair TF; Nakagawara A; De Bernardi B; Ambros PF; Pearson AD; Cohn SL; Matthay KK
    J Clin Oncol; 2011 Nov; 29(33):4358-64. PubMed ID: 21969516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
    Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hepatopathy in patients with stage 4S neuroblastoma].
    Claviez A; Hero B; Schneppenheim R; Berthold F
    Klin Padiatr; 1996; 208(4):221-8. PubMed ID: 8926687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroblastoma in Turkish children: experience of a single center.
    Aydn GB; Kutluk MT; Yalçn B; Büyükpamukçu M; Kale G; Varan A; Akyüz C; Senocak ME; Büyükpamukçu N
    J Pediatr Hematol Oncol; 2009 Jul; 31(7):471-80. PubMed ID: 19564739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroblastoma in adolescents: the Italian experience.
    Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
    Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.
    Laprie A; Michon J; Hartmann O; Munzer C; Leclair MD; Coze C; Valteau-Couanet D; Plantaz D; Carrie C; Habrand JL; Bergeron C; Chastagner P; Défachelles AS; Delattre O; Combaret V; Bénard J; Pérel Y; Gandemer V; Rubie H;
    Cancer; 2004 Sep; 101(5):1081-9. PubMed ID: 15329919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuroblastoma in children under than 1 year of age].
    Castel Sánchez V; Melero Moreno C; García-Miguel García-Rosados P; Navajas Gutiérrez A; Ruiz Jiménez JI; Navarro Fos S; Garín Valle JC; Galbe Sada M
    An Esp Pediatr; 1997 Dec; 47(6):584-90. PubMed ID: 9575117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma.
    Spitz R; Betts DR; Simon T; Boensch M; Oestreich J; Niggli FK; Ernestus K; Berthold F; Hero B
    Cancer Genet Cytogenet; 2006 May; 167(1):51-6. PubMed ID: 16682287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.
    Nickerson HJ; Matthay KK; Seeger RC; Brodeur GM; Shimada H; Perez C; Atkinson JB; Selch M; Gerbing RB; Stram DO; Lukens J
    J Clin Oncol; 2000 Feb; 18(3):477-86. PubMed ID: 10653863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroblastoma IV-S. A multicenter study. Work Group of Pediatric Oncology. Spanish Society of Pediatric Surgery].
    Rollán Villamarín V; García Aroca J; Costa Borrás E; Cuadros García J; Jiménez Alvarez C; Martínez-Caro A; Martínez Ibáñez V; Mulet Ferragut F; Obiols Arderius P; Pérez La Fuente G
    Cir Pediatr; 1994 Oct; 7(4):167-70. PubMed ID: 7865360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.
    Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
    Pediatr Blood Cancer; 2006 Mar; 46(3):278-84. PubMed ID: 16124002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
    Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
    J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.